Lung Cancer

Preliminary phase 2 study results show improved progression in NSCLC patients

Published in Cancer Weekly, June 21st, 2005

AstraZeneca reported the first results of a phase 2 study with ZD6474 at the 2005 American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida.

Trial 006, a randomized double-blind, placebo-controlled study, assessed the safety and efficacy of combining ZD6474 with the chemotherapy agent docetaxel (Taxotere) compared to docetaxel alone in patients with previously treated advanced non-small cell lung cancer (NSCLC).

Preliminary analysis of the trial 006 data showed that the primary endpoint of improved progression free survival (PFS) was met. Patients receiving ZD6474 100 mg plus docetaxel had a median PFS of 18.7 weeks, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-06-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry